The changing in vitro susceptibility pattern to pyrimethamine/ sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya

American Journal of Tropical Medicine and Hygiene

Volumn 62, Issue 3, 2000, Pages 396-401

  Mberu, E K ^a   Mosobo, M K ^a   Nzila, A M ^a   Kokwaro, G O ^a   Sibley, C H ^a   Watkins, W M ^a  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

FANSIDAR; PYRIMETHAMINE; SULFADOXINE;

ARTICLE; CHILD; CLINICAL TRIAL; DRUG SENSITIVITY; ENDEMIC DISEASE; HUMAN; INFANT; KENYA; MALARIA; NONHUMAN; PARASITE ISOLATION; PLASMODIUM FALCIPARUM;

EID: 0033775025     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2000.62.396     Document Type: Article

References (44)

1. Antimalarial drug resistance: The pace quickens
2. Malaria: Living with drug resistance
3. Chlorproguanil-dapsone: Effective treatment for uncomplicated falciparum malaria
4. Resistance to pyrimethamine/sulfadoxine in P. falciparum in 12 villages in northeast Tanzania and a test of chlorproguanil/dapsone
5. A randomized controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and Fansidar in the treatment of uncomplicated malaria in children
6. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: Dihydropteroate synthetase gene in lines of the human malaria parasite P. falciparum, with differing resistance to sulfadoxine
7. The dihydrofolate-thymidylate synthase gene in the drug resistance of malaria parasites
8. Molecular basis of differential resistance to cycloguanil and pyrimethamine in P. falciparum malaria
9. Community pyrimethamine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: A model for deterring resistance
10. Characterization of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine
11. Sulfadoxine resistance in the human parasite P. falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization
12. Allelic exchange at the endogenous genomic locus in P. falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria
13. Resistance to antifolates in P. falciparum monitored by sequence analysis of dihydropteroate synthase and dihydrofolate reductase alleles in a large number of field samples of diverse origins
14. Mutations in P. falciparum DHFR and DHPS and epidemiologic pattern of pyrimethamine-sulfadoxine use and resistance
15. Molecular assays for surveillance of antifolate-resistant malaria
16. The efficacy of antifolate antimalarial combination in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses
17. The rote of shops in the treatment and prevention of childhood malaria on the coast of Kenya
18. Child malaria treatment practices among mothers in Kenya
19. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: Selective pressure for resistance is a function of long elimination half-life
20. A study of the comparative bioavailability of pyrimethamine-sulfadoxine obtained from two oral preparations
21. Kenyan P. falciparum field isolates: Correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutation in the DHFR gene
22. The activity of proguanil and its metabolite, cycloguanil and p-chlorophenylbiguanide, against P. falciparum in vitro
23. Relationship between Plasmodium falciparum transmission by vector populations and the incidence of severe disease at nine sites on the Kenyan coast
24. Limited spatial clustering of individual Plasmodium falciparum alleles in field isolates from coastal Kenya
25. Polymorphism of the alleles of the merozoite surface antigens MSA1 and MSA2 in P. falciparum wild isolates from Colombia
26. Plasmodium falciparum: Selection of serine-108 of DHFR during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children
27. Antimalarial drug discovery: Development of inhibitors of DHFR active in drug resistance
28. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria
29. A preliminary pharmacokinetic study of the anti-malarial drugs, proguanil and chlorproguanil
30. Chlorproguanil/dapsone for the treatment of non-severe P. falciparum malaria in Kenya: A pilot study
31. In vitro activities of novel antifolate drug combinations against P. falciparium and human granulocyte CFUs
32. Chlorproguanil-dapsone for uncomplicated falciparum malaria in young children: Pharmacokinetics and therapeutic range
33. P. falciparum: Selective growth of sub-populations from field samples following in vitro culture, as detected by the polymerase chain reaction
34. In vitro susceptibility of Plasmodium falciparum isolates from Jilore, Kenya, to antimalarial drugs
35. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of P. falciparum
36. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in P. falciparum
37. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in P. falciparum
38. Antifolate-resistant mutants of P. falciparum dihydrofolate reductase
39. A modified in vitro sulfadoxine susceptibility assay for P. falciparum suitable for investigating Fansidar® resistance
40. Antibacterial synergism. A proposal for chemotherapeutic potentiation between trimethoprim and sulfamethoxazole
41. Potentiating effect of pyrimethamine and sulfadoxine against DHFR from pyrimethamine-sensitive and pyrimethamine-resistant P. chabaudi
42. Comments on 'The efficacy of antifolate antimalarial combination in Africa'
43. More on 'The efficacy of antifolate antimalarial combination in Africa'
44. Selection and synergy in P. falciparum